#1 Clinical Trials Search in Europe

Bhv-7000

BHV-7000 is an investigational drug currently being studied in clinical trials for various neurological and psychiatric conditions. These trials aim to evaluate the safety, tolerability, and efficacy of BHV-7000 in treating refractory focal epilepsy, idiopathic generalized epilepsy, bipolar disorder, and major depressive disorder. The studies involve different dosages and treatment durations to determine the optimal use of this potential new medication.

Table of Contents

What is BHV-7000?

BHV-7000 is a new investigational drug that is currently being studied for its potential to treat several neurological and psychiatric conditions[1]. It is not yet approved for use by regulatory agencies like the FDA, but it is undergoing extensive clinical trials to determine its effectiveness and safety.

What Conditions Does BHV-7000 Treat?

Based on the ongoing clinical trials, BHV-7000 is being investigated for the treatment of several conditions:

  • Epilepsy: Specifically, it’s being studied for:
    • Refractory focal onset epilepsy[1][2][3]
    • Idiopathic generalized epilepsy with generalized tonic-clonic seizures[8]
  • Bipolar Disorder: Particularly for the treatment of manic episodes in bipolar I disorder[4][6]
  • Major Depressive Disorder (MDD)[5][7]

Let’s break down these conditions:

Epilepsy is a neurological disorder characterized by recurrent seizures. Refractory focal onset epilepsy refers to a type of epilepsy where seizures start in one specific area of the brain and don’t respond well to current treatments. Idiopathic generalized epilepsy with generalized tonic-clonic seizures is a type where seizures affect the entire brain from the start and cause loss of consciousness and violent muscle contractions.

Bipolar Disorder is a mental health condition characterized by extreme mood swings, including emotional highs (mania or hypomania) and lows (depression). Bipolar I disorder specifically involves manic episodes that last at least 7 days or are severe enough to require immediate hospital care.

Major Depressive Disorder (MDD), also known as clinical depression, is a mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life.

How Does BHV-7000 Work?

The exact mechanism of action of BHV-7000 is not explicitly stated in the provided clinical trial information. However, based on its potential uses, it likely acts on the central nervous system to regulate brain activity and neurotransmitter balance. Further research and published studies would be needed to provide more detailed information on how BHV-7000 works in the body.

Current Clinical Trials

BHV-7000 is currently undergoing several clinical trials to evaluate its efficacy and safety:

  • Phase 2/3 trials for refractory focal onset epilepsy[2][3]
  • A long-term safety study for refractory focal onset epilepsy[1]
  • A Phase 2/3 trial for acute treatment of manic episodes in bipolar I disorder[6]
  • A Phase 2 trial for major depressive disorder[7]
  • Open-label extension studies for bipolar disorder and major depressive disorder[4][5]
  • A Phase 2/3 trial for idiopathic generalized epilepsy with generalized tonic-clonic seizures[8]

These trials aim to determine how effective BHV-7000 is in treating these conditions, as well as to assess its safety and tolerability in patients.

Dosage Information

In the clinical trials, BHV-7000 is being tested at various dosages:

  • 25 mg, 50 mg, or 75 mg taken once daily for epilepsy[2][3]
  • 75 mg taken once daily for bipolar disorder and major depressive disorder[6][7]

It’s important to note that these dosages are still being studied and may change based on the results of the clinical trials. The optimal dosage for each condition will be determined through these studies.

Safety and Side Effects

As BHV-7000 is still in clinical trials, its full safety profile is not yet established. The trials are closely monitoring for any adverse events (side effects) that may occur. Some of the safety measures being assessed include:

  • Serious adverse events (SAEs)
  • Adverse events leading to discontinuation of the drug
  • Moderate or severe adverse events
  • Clinically significant laboratory abnormalities
  • Vital sign abnormalities
  • Electrocardiogram (ECG) abnormalities, specifically QTc elevation[6]

It’s important to remember that all medications can have side effects, and the purpose of these clinical trials is to determine if the potential benefits of BHV-7000 outweigh any risks.

Future Prospects for BHV-7000

The ongoing clinical trials for BHV-7000 are promising, as they cover a range of neurological and psychiatric conditions. If these trials show positive results, BHV-7000 could potentially become a new treatment option for patients with epilepsy, bipolar disorder, or major depressive disorder who haven’t responded well to existing treatments.

However, it’s important to note that drug development is a long and complex process. Even if the clinical trials show positive results, BHV-7000 would still need to go through regulatory approval processes before it could be made available to patients. This process ensures that any new medication is both safe and effective before it reaches the public.

Patients interested in BHV-7000 should discuss with their healthcare providers about the possibility of participating in clinical trials or staying informed about the drug’s development progress.

Aspect Details
Drug Name BHV-7000
Conditions Studied Refractory Focal Epilepsy, Idiopathic Generalized Epilepsy, Bipolar I Disorder, Major Depressive Disorder
Study Phases Phase 2 and Phase 2/3
Dosages 25 mg, 50 mg, 75 mg (once daily)
Primary Outcomes Change in seizure frequency, change in YMRS scores, change in MADRS scores
Safety Assessments Adverse events, laboratory abnormalities, vital signs, ECG changes
Study Designs Randomized, double-blind, placebo-controlled; some with open-label extensions
Treatment Durations Ranging from 21 days to 24 weeks, with some long-term safety studies

FAQ

  • What conditions is BHV-7000 being studied for? BHV-7000 is being studied for several conditions, including refractory focal epilepsy, idiopathic generalized epilepsy with generalized tonic-clonic seizures, bipolar disorder (specifically manic episodes), and major depressive disorder.
  • How is BHV-7000 administered in these trials? In most trials, BHV-7000 is administered orally once daily. The dosages being studied range from 25 mg to 75 mg, depending on the specific trial and condition being treated.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety, tolerability, and efficacy of BHV-7000. Researchers are looking at how well it reduces seizure frequency in epilepsy patients, improves symptoms in bipolar mania, and alleviates depression in major depressive disorder.
  • How long do these clinical trials last? The duration of the trials varies. Some epilepsy trials last 8 to 12 weeks, while others, like the bipolar mania study, last 21 days. There are also long-term safety studies that may continue for extended periods to assess the drug's effects over time.
  • What are some of the key measures used in these trials? Key measures include changes in seizure frequency for epilepsy trials, the Young Mania Rating Scale (YMRS) for bipolar mania, and the Montgomery-Åsberg Depression Rating Scale (MADRS) for depression. Safety is assessed through monitoring adverse events, laboratory tests, vital signs, and ECG abnormalities.

Ongoing Clinical Trials on Bhv-7000

  • Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

    Recruiting

    1 1
    Investigated drugs:
    Denmark Finland Germany Greece Hungary Italy +5

  • Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

    Recruiting

    1
    Investigated drugs:
    Austria Belgium Croatia Czechia France Hungary +3

  • Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

    Recruiting

    1 1
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark Finland +12

  • Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium Croatia Finland France Germany +5

Glossary

  • Refractory Focal Epilepsy: A type of epilepsy where seizures originate in a specific area of the brain and do not respond well to standard anti-epileptic medications.
  • Idiopathic Generalized Epilepsy: A group of epilepsy syndromes that are believed to have a strong genetic component and typically involve seizures that affect both sides of the brain from the start.
  • Bipolar I Disorder: A mental health condition characterized by alternating episodes of mania (extreme highs) and depression.
  • Major Depressive Disorder (MDD): A mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life.
  • Young Mania Rating Scale (YMRS): A clinical tool used to assess the severity of manic symptoms in patients with bipolar disorder.
  • Montgomery-Åsberg Depression Rating Scale (MADRS): A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
  • Double-blind: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in clinical trials.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • QTc: The heart rate-corrected QT interval, a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. Prolongation of this interval can indicate a risk for certain heart rhythm abnormalities.

References